Show simple item record

dc.contributor.authorFarabi, Hen_US
dc.contributor.authorRezapour, Aen_US
dc.contributor.authorMoradi, Nen_US
dc.contributor.authorAghamir, SMKen_US
dc.contributor.authorKoohpayehzadeh, Jen_US
dc.date.accessioned2024-05-30T13:26:42Z
dc.date.available2020-11-05en_US
dc.date.issued2020-12-09en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/97111
dc.description.abstractBACKGROUND: This study aimed to review studies on willingness to pay (WTP) for prostate cancer screening. METHODS: This systematic-review was conducted based on the Preferred Reporting Items for Systematic Reviews guidelines. By searching six-health-database, WTP studies on prostate cancer screening using contingent valuation method published in English until March 2020 were included and those with unavailable full-text and inadequate quality-assessment scores were excluded. Smith checklist was used for the quality assessment. Extracted WTPs were converted to US dollar in 2018 using exchange rate parity and net present value formula to make comparison. Factors' effect was assessed by vote counting. RESULTS: Six final studies published after 2006 reported above 70% Smith checklist items needed to be considered in contingent valuation study reports. Seven factors have positive effects on WTP. The reported WTP value varied from 11$ to 588$ in Japan and Germany, respectively. CONCLUSION: WTP for prostate cancer screening was positive among all studied men. The results of factors' effect assessment showed that better understanding prostate cancer risks or screening tests and factors such as age, income, family history of cancer, hospitalization history, and educational level have positive effects. Moreover, prostate-specific antigen history, health insurance, employment, and subject's health assessment received less attention. The results' generalization to all countries is not applicable because there are no studies for low- and middle-income countries. SYSTEMATIC REVIEW REGISTRATION: PROSPERO 2020 CRD42020172789.en_US
dc.format.extent290 - ?en_US
dc.languageengen_US
dc.relation.ispartofSyst Reven_US
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
dc.subjectContingent valuation methoden_US
dc.subjectEarly detectionen_US
dc.subjectProstate cancer screeningen_US
dc.subjectSystematic reviewen_US
dc.subjectWillingness to payen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectEarly Detection of Canceren_US
dc.subjectGermanyen_US
dc.subjectInsurance, Healthen_US
dc.subjectProstate-Specific Antigenen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectSurveys and Questionnairesen_US
dc.titleMen's willingness to pay for prostate cancer screening: a systematic review.en_US
dc.typeArticle
dc.identifier.doi10.1186/s13643-020-01522-3en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/33298175en_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
pubs.volume9en_US
dcterms.dateAccepted2020-11-05en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record